AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy'
AstraZeneca has struck a $1bn (£773m) deal to buy a Belgian biotech company that specialises in cancer immunotherapies, the latest in a string of acquisitions that also yielded positive results for a late-stage rare disease drug on Monday.
EsoBiotec, a small privately held firm founded four years ago in Mont-Saint-Guibert, develops in-vivo cell therapies that empower the immune system to attack cancers, and could offer many more patients access to cell therapy treatments provided in minutes rather than weeks.
The deal marks the latest acquisition by Astra, which is Britain's biggest listed company valued at £186bn, as the pharmaceutical group continues to expand its global operations.
EsoBiotec's treatment uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T-cells, which program them to recognise and destroy tumour cells for cancer treatment, or tackle autoreactive cells (that target the body's own tissues or cells) for potential use in autoimmune diseases. This means cell therapies can be administered through a simple injection, and EsoBiotec describes them as 'cost-effective, off-the-shelf therapies'.
In traditional cell therapies, cells are taken from a patient, genetically modified outside the body, and then put back into the patient as a medicine after immune cell depletion, which usually takes weeks.
Susan Galbraith, the executive vice-president of oncology research and development at AstraZeneca, said: 'We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them.
'EsoBiotec will accelerate and expand the impact of our recent investments and marks a major step forward in realising our ambition to harness the full potential of cell therapy.'
EsoBiotec recently launched a clinical trial for multiple myeloma, a type of bone marrow cancer.
AstraZeneca, which fended off a hostile £69bn takeover approach from the US group Pfizer in 2014, will pay $425m initially for the Belgian company, and up to $575m based on development and regulatory milestones. It has been beefing up its drug portfolio with targeted acquisitions, such as China's Gracell Biotechnologies, which specialises in cancer therapy known as CAR-T that modifies a patient's cells to fight the disease.
AstraZeneca's biggest deal was the $39bn acquisition of the US rare disease drug developer Alexion in 2020, but it was criticised for paying a high price. Marc Dunoyer, who runs the division and is AstraZeneca's chief strategy officer, defended the deal as a 'fantastic acquisition' last month when the company took a $753m hit for scrapping one of the Alexion drugs, while two other products from the acquisition have also been abandoned.
Separately, Britain's biggest pharmaceutical group said on Monday that its Imfinzi treatment had been approved in the EU as the first and only immunotherapy for patients with limited-stage small cell lung cancer, whose disease has not progressed after platinum-based chemoradiation therapy.
Sign up to Business Today
Get set for the working day – we'll point you to all the business news and analysis you need every morning
after newsletter promotion
AstraZeneca also announced that a drug for a rare endocrine disease, hypoparathyroidism, which can lead to bone density loss and osteoporosis, had met its goal of normalising calcium levels in the blood after 24 weeks. It was well tolerated by patients, and the trial continues as planned to 52 weeks. The company acquired the medicine along with the French rare disease specialist Amolyt Pharma in a deal worth more than $1bn a year ago.
AstraZeneca also announced a licence agreement with South Korea's Alteogen to acquire the worldwide rights to its platform, to develop and commercialise subcutaneous formulations of several oncology medicines.
Injecting medicines into the fatty tissue just under the skin can offer many advantages, including time savings for patients, clinical staff and health systems.
AstraZeneca's share price reaction was muted, dipping by 0.3%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Belfast Telegraph
a day ago
- Belfast Telegraph
I could have closed gap to Celtic, insists former Rangers boss Philippe Clement
Clement felt he was working on a long-term project after the board told him to cut the wage bill last summer and develop younger players to fuel future spending. But his reign ended in February after back-to-back home defeats by Queen's Park and St Mirren left them out of the Scottish Cup and 13 points adrift of Celtic in the Premiership. Russell Martin has now been installed as his permanent successor after an interim stint from Barry Ferguson and the financial backdrop has changed following a takeover by an American consortium. 'It's a pity that the story stopped, that the board didn't have the patience or maybe listened too much to some fans,' Clement told BBC Scotland. 'There are other clubs where there is a difficult moment and everybody sticks together because everybody knows the story, how the work is done inside the building, and they continue and they are successful afterwards. 'In three or four windows, we could have closed the gap with a good development of players, but the decision is made and you need to accept it.' Clement pointed out that this time last year he was told the club's spending was not sustainable 'There was not fresh investment in the club, but the money available for the transfers would be the sale of players, so the amount you can get out of that,' he added. 'That was not much at the end, because the squad was with a lot of older players. So people didn't want to pay any more for them. Six players were out of contract, so they left for free.' The Belgian added that the wage bill was cut by 35 per cent in order to rebuild the squad. 'And the idea was, and that was clearly said at the board, that the club needed three, four transfer windows to get at the level of Celtic, because you have to gain money again by bringing young players in, developing them, making them better, selling them and getting money to make the squad better and better in the next two, three years,' he added. Clement believes progress has been made in that sense with the development of the likes of Nico Raskin, Jefte, Hamza Igamane and Clinton Nsiala. 'If they say there's no new investment, I now understand why,' he said. 'Because at the end, some people were already thinking about selling the club and selling their stocks.' Clement claimed Rangers under-achieved domestically but over-achieved in the Europa League and felt some players were not ready for the demands of competing on both fronts. 'I think it's normal in the financial situation the club was, but it's not good enough,' he said. 'But you need patience then to build it or you need to spend money. It's one of the two. Without one of the two, it's an impossible job.' Clement hopes his successor gets that backing. 'I hope that there comes stability, to work in a good way with the players, with the staff, with everybody in the club, to have a consistent story,' he said. 'I think that's a big part that the club has been lacking for years and I hope that the new owners can bring that for the club and for the manager also, for the players.'
The National
2 days ago
- The National
Clement names five Rangers stars who can make club money
Gers have been criticised for their player trading model over the years, one of the factors in them falling behind Celtic who have sold Kieran Tierney, Jota and Matt O'Riley, among others, for huge sums. It was something Clement bemoaned while manager as the club allowed the likes of Ryan Kent and Alfredo Morelos to see out their deals and move on for nothing, when there may have been chances to cash in earlier. However, the likes of Hamza Igamane and Nicolas Raskin have been attracting transfer interest having shown they can be assets. And the Belgian reckons they're not the only ones - adding Jefte, Clinton Nsiala and Mohamed Diomande to that. "But you also have Jefte, Hamza Igamane, Clinton Nsiala, who will have a better value. Mohamed Diomande is also one of those guys. "The club has worked well the past year in that way. "There are now four or five players with the value to sell and several teams would pay good amounts of money. "The club needs to build with that, or the new owners have to say 'we don't do it that way now because we have enough money'."
Metro
3 days ago
- Metro
‘Mouth-watering' chocolate brand that disappeared from supermarkets is back
The big UK supermarkets aren't exactly short of options when it comes to chocolate, with own-brand bars and treats, as well as products by big names like Cadbury, Tony's and Nestlé. But there's one brand that's been notably missing from the likes of Tesco and Sainsbury's for the last five years as it swapped supermarket shelves for luxury retailers, and that's GODIVA. Founded in Brussels in 1926, the chocolate brand began with pralines and the business is named after the legend of Lady Godiva. It's been sold in the UK for years in high-end stores like Harrods and Selfridges and even has its own flagship store in Covent Garden, but the chocolates haven't been widely available in supermarkets. GODIVA's first foray into supermarkets came in 2017, when the brand partnered with Sainsbury's to sell its Belgian chocolates, but it disappeared from shelves there in 2020. However, that's all about to change as the 100-year-old brand is making a supermarket comeback and has just launched its version of the viral Dubai chocolate bar in Tesco. But, of course, there's a catch. The chocolate treat – a Pistacho & Kadayif bar which sees GODIVA milk chocolate wrapped around crunchy pistachios and crispy Kadayif pastry pieces – is only available at Tesco for a limited time. And when we say limited, we aren't joking. Shoppers now have just over a week to get their hands on it at their local supermarket, as it'll only be sold there until June 17. What's more, the premium bar doesn't come cheap with an RRP of £10, though those with a Clubcard will be able to save a little, getting it for £7.95. According to GODIVA, this new bar is a reimagined and more accessible version of their usual Dubai-style chocolate bar, which is sold in Harrods for £24.95. Speaking about the launch, Isabella Rogers, chief marketing officer at GODIVA, said: 'Inspired by the viral Dubai-style chocolate trend, our new GODIVA Crispy Kadayif & Pistachio Chocolate offers an effortless way for more people to experience our premium take on this indulgent sensation for a limited time only on the high street. 'From the signature GODIVA milk chocolate couverture to the delicate crunch of pistachios and crisp golden Kadayif, it's a true feast for the senses – designed for those who may not make it to our Covent Garden boutique but still want a taste of luxury.' The brand has a strong fan base, with reviewers on Yelp hailing it as 'expensive but well worth it', 'the finest chocolates to be had in the capital', 'mouth-watering' and 'the best chocolate in London' and 'delicious' in numerous four and five star posts about the Covent Garden chocolate shop. This comes after a number of other chocolate brands recently shared exciting news, including Cadbury. The iconic brand has unveiled brand new Dairy Milk bars for summer, with one new flavour plus fun colour-changing packaging. There's an Iced Latte Dairy Milk chocolate bar, which combines smooth coffee cream, biscuit pieces and the classic taste of Cadbury chocolate and four temperature-activated packets, which visually transform when the chocolate is chilled. Yes, that's right, in a somewhat unexpected move, Cadbury is actively encouraging people to put their chocolate bars in the fridge. More Trending The new cold-activated packs will look like ordinary purple Dairy Milk bars – until they are popped in the fridge. Using thermochromic technology, the temperature change will reveal one of four vibrant summer-themed designs as the wrapper changes colour to reveal a deep blue image. Elsewhere, Mars Wrigley, has just confirmed that the 'best' Maltesers are making a comeback after 11 years. (That's the white chocolate version, in case you didn't know.) First launched in 2003, White Chocolate Maltesers were a fan-favourite before being discontinued in 2014 and people have spent more than a decade begging for them to return. View More » White Chocolate Maltesers will be available in treat bags, single bag and sharing bag formats from June 16. You'll be able to find them in major supermarkets along with independent retailers too, so you won't have to go far to get your fix. Do you have a story to share? Get in touch by emailing MetroLifestyleTeam@ MORE: 'Power picnics' are perfect for summer — but you have to follow five rules MORE: Major US fast food chain to open in London Heathrow airport – a European first MORE: Tesco launches major new Clubcard bonus — but shoppers need to act fast Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.
